Company: STAA
Filing Date: 2025-09-26
Form Type: DEFA14A
Source: 0001193125-25-219844
Chunk: 34

Company: STAAR SURGICAL CO
Filing Date: 2025-09-26
Form: DEFA14A
Chunk 34
---
 control of the company without paying a control premium Broadwood supports STAAR’s “appointments of directors with an understanding of shareholder alignment and a deep understanding of the global medical device industry, particularly in Asia (from which approximately 80% of the Issuer's revenue is derived).“ Broadwood Schedule 13D filed 3.3.25 Broadwood is “impressed with the new CEO's operational experience and history of successfully and profitably growing global businesses.” Broadwood Schedule 13D filed 3.3.25 EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

Based on private conversations with stockholders, STAAR knows that Broadwood’s views are not shared by all STAAR stockholders Broadwood is asking stockholders to forfeit the all-cash, premium value provided by the Alcon merger and bear STAAR’s significant risks as a standalone company Soleus Capital, which owns ~6%(1) of STAAR’s outstanding shares, said, “Soleus Capital Master Fund, L.P. has informed the Board that it is supportive of the merger and intends to vote in favor absent a material change in circumstance.” September 19, 2025 2nd Largest Active STAAR Stockholder Supports Alcon Transaction Source: FactSet. Market data as of 9/25/2025. (1) Reflects holdings data as of 6/30/2025 13F. Market is confident that the transaction will close at $28.00 per share, reflected by the spread between current share price and offer price Share Price as of September 25, 2025: $26.75 (4.5%) vs Offer Price VWAP Since Announcement: $27.15 (3.0%) vs Offer Price EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

STAAR expects that its valuation would face considerable downward pressure in the event of a vote against the deal STAAR’s future direction controlled by a single minority stockholder at the expense of the majority Risk of creeping control by Broadwood a likely drag on valuation Ongoing risks related to standalone prospects Threatened dismissal of existing Board and management, with new team hand-picked by Broadwood ― given Broadwood’s significant input on STAAR over 30+ years, it is unclear how STAAR’s other stockholders would benefit